Lv71
4970 积分 2023-05-22 加入
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
12天前
已完结
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
12天前
已完结
Definitive intensity-modulated radiotherapy for organ preservation in vulvar cancer: A multicenter study
12天前
已完结
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study
12天前
已完结
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
12天前
已完结
Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab maintenance therapy in ovarian cancer: Results from the phase 22870-002/SKB264-II-06 study
12天前
已关闭
LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial
13天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
13天前
已完结
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer
13天前
已完结
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
13天前
已完结
皖公网安备34019202002308
